SPP100

New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension

-FIXED DOSE COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BY FDA- BASEL, Switzerland and BRIDGEWATER, NJ, 21 May 2007 - Speedel (SWX: SPPN) today welcomed the significant new results from clinical trials of SPP100 (aliskiren, Tekturna/Rasliez[1]) presented by investigators at the 22nd Annual Sc...

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

...ting to see the first follow-on renin inhibitor to spp100 demonstrate its potential in diabetic patients in ... manage patient group has been shown to respond to spp100 to controlling blood pressure alone and in combina...reating cardiovascular diseases. Our lead compound spp100 (Tekturna/Rasilez [i]), the first-in-class direct ...

SPP100 in Biological Technology

Anavex appoints Dr. Dimitri Goundis to lead Clinical Development

...peedel AG. During his tenure, Dr. Goundis led the successful development of spp100 from Phase I through Phase IIb clinical trials, at which time Novartis exercised its license-back option. Today, spp100 is sold in the United States under the trade name Tekturna and in Europe un...

SPP100 in other areas

Quatech SPP100 - NexTag.com

Compare prices for deals on Quatech SPP100 at NexTag.com. Find bargains on computers, electronics, software, and more.

SPP100 (Tekturna/Rasilez) Promising Results In Patients With Heart Failure

Speedel (SWX: SPPN) welcomed the promising results of SPP100 (Tekturna/Rasilez[1]) in a Phase II clinical trial with heart failure patients which were announced by ...

SPP100 (Tekturna/Rasilez) Reduces Left Ventricular Hypertrophy

Speedel (SWX: SPPN) welcomed promising results from the latest SPP100 (Tekturna/Rasilez[1]) surrogate marker clinical trial which were announced by Novartis and ...

Second Major Milestone For Speedel Pharmaceuticals, Inc. In Its Goal To ...

SPP100 is the first-in-class once daily oral renin inhibitor that Speedel ... Speedel believes that SPP100 has a five year lead over the next generation of ...

Heart Disease - Biopharmaceutical company releases results of clinical ...

NewsRx is the leading source of news and information on Heart Disease ... SPP100 (Aliskiren) is the first-in-class renin inhibitor being developed for the ...